000			05335cam a2200493Ii 4500
999			_c96543 _d96543 _x1
001			96543
003			ES-MaUEC
005			20230102112759.0
006			m o d
007			cr |n|||||||||
008			170926s2017 sz ob 000 0 eng d
020			_a3319545795 _q(electronic bk.)
020			_a9783319545790 _q(electronic bk.)
020			_z3319545787
020			_z9783319545783
040			_aYDX _beng _erda _cYDX _dN$T _dEBLCP _dGW5XE _dN$T _dNJR _dAZU _dUPM _dCOO _dCOD _dNOC _dMERER _dES-MaUEC _bspa
050		4	_aQP101 _b2017 EB
245	0	0	_aMicrodomains in the cardiovascular system _cViacheslav Nikolaev, Manuela Zaccolo, editors.
264		1	_aCham, Switzerland _bSpringer International Publishing
264		4	_c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aCardiac and vascular biology _x2509-7830
500			_a
504			_aIncluye referencias bibliográficas
505	0		_aPreface; Contents; Part I: Cyclic Nucleotide Microdomains; 1: Receptor-Cyclic Nucleotide Microdomains in the Heart; 1.1 Introduction; 1.2 Biosensors for cAMP and cGMP; 1.3 Mechanisms of Compartmentation in Microdomains; 1.4 Receptor-cAMP/cGMP Microdomain Visualization; References; 2: Membrane Microdomains and cAMP Compartmentation in Cardiac Myocytes; 2.1 Introduction; 2.2 Membrane Microdomains; 2.3 Receptor-Mediated Responses; 2.3.1 ß1-Adrenergic Receptors (ß1ARs); 2.3.2 ß2-Adrenergic Receptors (ß2ARs); 2.3.3 M2 Muscarinic Receptors (M2Rs); 2.3.4 Prostaglandin Receptors (EPRs)
505	8		_a2.4 Conclusions and Future DirectionsReferences; 3: Function to Failure: Compartmentalization of Cardiomyocyte Signaling by A-Kinase-­Anchoring Proteins; 3.1 Introduction; 3.2 AKAPs and Regulation of the Calcium Cycle; 3.2.1 AKAP7 (Small Isoforms); 3.2.2 AKAP7 (Large); 3.2.3 AKAP5 (AKAP75/AKAP79/AKAP150); 3.3 AKAPs and Cardiac Remodeling; 3.3.1 AKAP6; 3.3.2 AKAP13; 3.4 Other AKAPs with Characterized Functions; References; 4: Pharmacological Approaches for Delineating Functions of AKAP-­Based Signalling Complexes and Finding Therapeutic Targets; 4.1 Introduction
505	8		_a4.1.1 The cAMP Signalling Cascade4.1.2 cAMP Effectors; 4.1.3 cAMP Signalling Compartments; 4.2 A-Kinase Anchoring Proteins (AKAPs); 4.2.1 AKAP-PKA Interactions; 4.2.2 The Role of AKAPs in the Heart and Cardiovascular Diseases Exemplifies Their Potential Value as Drug Targets; 4.3 AKAP-PKA Disruptors; 4.3.1 Peptides; 4.3.1.1 Binding to R-Subunits of PKA; 4.3.1.2 Binding to AKB Domains of AKAPs; 4.3.1.3 Modified Peptides; 4.3.2 Peptidomimetics; 4.3.3 Small Molecules; 4.3.4 Disruptors of Interaction Between AKAPs and Proteins Other Than PKA; 4.4 Conclusions and Outlook; References
505	8		_a5: Chatting Second Messengers: PIP3 and cAMP5.1 Introduction; 5.2 PIP3: A Signaling Lipid on Membranes; 5.3 Mechanisms of Cross-Talk between PIP3 and cAMP Signaling; 5.3.1 PIP3-Mediated Downregulation of ß-AR/cAMP Signaling in Heart Failure; 5.3.2 PIP3- and PI3K-Dependent Control of cAMP Hydrolysis; 5.3.3 cAMP-Mediated Regulation of PIP3 Signaling; References; 6: Cyclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart; 6.1 Introduction; 6.2 CN Signalling in Cardiac Myocytes; 6.3 Overview of the PDE Superfamily
505	8		_a6.4 Role of PDEs in Cyclic Nucleotide Compartmentation6.5 PDEs and Cyclic Nucleotide Compartmentation in Heart Failure; 6.6 PDEs as Therapeutic Targets in Ischemia/Reperfusion Injury?; 6.7 Concluding Remarks; References; 7: cAMP Compartmentalisation and Hypertrophy of the Heart: 'Good' Pools of cAMP and 'Bad' Pools of cAMP Coexist in the Same Cardiac Myocyte; 7.1 cAMP Signalling in the Heart; 7.2 Compartmentalisation of the cAMP Signalling Pathway; 7.3 Compartmentalisation of GPCRs and ACs; 7.4 PKA Compartmentalisation via AKAPs; 7.5 PDEs and cAMP Compartmentalisation
520	3		_aThe book comprehensively presents new findings in cardiovascular research related to signaling microdomains in health and disease. Important second messengers such as cAMP, cGMP, calcium and their role in microdomain signaling are discussed. The book offers and explains methodical approaches and technical ways how to successfully analyze microdomain signaling, also in the context of disease. It further provides scientific perspectives and strategies that are based on the concept of signaling within microdomains and that can revolutionize pharmacology and eventually lead to the effective treatment of cardiovascular diseases in future. This book is written for scientists in cardiovascular research, pharmacology, molecular and cellular biology as well as medical doctors in cardiology, angiology and nephrology. .
588	0		_aVersión impresa
988			_aEBOOK, EBSPRINGER_2017
650		7	_2embne _9138556 _aAparato circulatorio
650		7	_2embne _aFisiología _9138487
700	1		_aNikolaev, Viacheslav.
700	1		_aZaccolo, Manuela.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-54579-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2018 _dz _e- _zSI